Previous Article | Next Article ![]()
Infection and Immunity, May 2000, p. 2638-2646, Vol. 68, No. 5
Department of Microbiology, Technical
University of Denmark, DK-2800 Lyngby,
Denmark,1 and Department of
Microbiology, University of Washington, Seattle, Washington
981952
Received 30 November 1999/Returned for modification 12 January
2000/Accepted 3 February 2000
Type 1 fimbriae are surface organelles of Escherichia
coli which mediate D-mannose-sensitive binding to
different host surfaces. This binding is conferred by the minor
fimbrial component FimH. Naturally occurring variants of the FimH
protein have been selected in nature for their ability to recognize
specific receptor targets. In particular, variants that bind strongly
to terminally exposed monomannose residues have been associated with a
pathogenicity-adaptive phenotype that enhances E. coli
colonization of extraintestinal locations such as the urinary bladder.
In this study we have used random mutagenesis to specifically identify
nonselective mutations in the FimH adhesin which modify its binding
phenotype. Isogenic E. coli clones expressing FimH variants
were tested for their ability to bind yeast cells and model
glycoproteins that contain oligosaccharide moieties rich in either
terminal monomannose, oligomannose, or nonmannose residues. Both the
monomannose- and the oligomannose-binding capacity of type 1 fimbriae
could be altered by minor amino acid changes in the FimH protein. The
monomannose-binding phenotype was particularly sensitive to changes,
with extensive differences in binding being observed in comparison to
wild-type FimH levels. Different structural alterations were able to
cause similar functional changes in FimH, suggesting a high degree of flexibility to target recognition by this adhesin. Alteration of
residue P49 of the mature FimH protein, which occurs within the
recently elucidated carbohydrate-binding pocket of FimH, completely abolished its function. Amino acid changes that increased the binding
capacity of FimH were located outside receptor-interacting residues,
indicating that functional changes relevant to pathogenicity are likely
to be due to conformational changes of the adhesin.
Bacterial adherence is normally
critical for successful colonization of a specific host tissue. The
best-characterized group of bacterial adhesins is constituted by
fimbriae (11). Type 1, or mannose-sensitive, fimbriae are
found on the majority of Escherichia coli strains and are
widespread among other members of the Enterobacteriaceae
(15). Interaction between type 1 fimbriae and receptor
structures plays a key role in the colonization of various host tissues
by E. coli (1, 36). Also, in certain strain
backgrounds, type 1 fimbriae can be regarded as virulence factors.
Indeed, we and others have previously shown that the expression of type
1 fimbriae in E. coli is linked to urinary tract
pathogenesis (5, 22). In mouse models, immunizations with
FimH and synthetic FimH peptides were shown to prevent urogenital mucosal infection by E. coli (19, 35).
A typical type 1 fimbriated bacterium has 200 to 500 peritrichously
arranged fimbriae on its surface. A single type 1 fimbria is a
7-nm-wide, approximately 1-µm-long rod-shaped structure consisting of
four different components that are added to the base of the growing
organelle (21). The bulk of the structure is made up of
about 1,000 copies of the major subunit protein, FimA, polymerized into
a right-handed helical structure, but small quantities of the minor
components, FimF, FimG, and FimH, are also present (12, 18).
The receptor-recognizing element of type 1 fimbriae is the 30-kDa FimH
protein (17). The FimH protein is located at the tip of the
fimbria and is also interspersed along the fimbrial shaft (9,
17). The FimF and FimG components are probably required for
integration of the FimH adhesin into the fimbriae (9, 12).
The components of the fimbrial organelle are encoded by the
chromosomally located fim gene cluster (14). In
addition to the structural components, this 9.5-kb DNA segment encodes
the fimbrial biosynthesis machinery as well as regulatory elements (Fig. 1). The fimbrial organelle
components, FimA, FimF, FimG, and FimH, are produced as precursors
having an N-terminal signal sequence. This sequence is subsequently
removed during export across the inner membrane. Thus, the FimH protein
is produced as a precursor of 300 amino acids that is processed into a
mature form of 279 amino acids (7, 12). Further export from
the periplasm and across the outer membrane is dependent on a
fimbria-specific export and assembly system constituted by the FimC and
FimD proteins (8, 10, 13).
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Functional Flexibility of the FimH Adhesin:
Insights from a Random Mutant Library
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

View larger version (17K):
[in a new window]
FIG. 1.
Overview of the plasmids used to display FimH variants.
Only relevant nonvector regions are shown. (A) Plasmid pPKL115 contains
the entire fim gene cluster with a translational stop linker
inserted into the fimH gene (triangle). (B) The
fimH expression vector pMAS1 is shown along with the
strategy employed to introduce random mutations into the receptor
recognition domain of the fimH gene. Primers ms3 and ms7 are
described in Materials and Methods.
By virtue of the FimH adhesin, type 1 fimbriae mediate adhesion to a variety of mannosylated glycoproteins. The affinity of FimH variants toward mannose targets can vary due to changes in the primary structure of this protein. In about 80% of fecal E. coli isolates, the FimH adhesin is capable only of binding to trimannose receptors. In contrast, the FimH adhesins from approximately 70% of urinary tract isolates carry minor mutations (compared to the fecal isolates) which enhance their ability to recognize monomannose receptors (33). The mutant alleles confer a significantly higher tropism for the uroepithelium and dramatically enhance the ability of E. coli to colonize the mouse urinary tract (31). Some of the monomannose-binding E. coli strains are also capable of recognizing complex oligosaccharides with no terminally exposed mannose residues (34). Additionally, a recent study has revealed that FimH adhesins from meningitis-associated isolates of E. coli confer binding to collagens and that this specificity change is due to a minor variation in the amino acid sequence of FimH (25).
All FimH variants and their corresponding adhesive profiles described hitherto have been characterized from fecal or clinical strains selected to play a specific role in nature, namely, interaction with mammalian host surfaces. Naturally occurring fimH mutants, adapted to enhance the colonization of either commensal intestinal or pathogenic extraintesintal niches, might therefore have a relatively tight group of receptor affinities that can be invoked only by highly specific structural changes. With a view to probing the binding potential of the FimH adhesin more extensively, we have created a random mutant library based on the fimH gene from E. coli K-12 strain PC31 and analyzed the functional impact of nonselective mutations.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Bacterial strains, plasmids, and growth conditions.
The
strains and plasmids used in this study are listed in Table
1. The E. coli K-12 strain
HB101 (F' lacI kan) (2) was used as an
intermediate host during plasmid construction work. All subsequent
phenotypic analyses were performed with the E. coli
fim
strain S1918 (3). Cells were grown in Luria-Bertani (LB)
broth (26) supplemented with the appropriate antibiotics.
|
DNA techniques. Plasmid DNA was isolated using the QIAprep spin plasmid kit (Qiagen). Restriction endonucleases were used as specified by the manufacturer (Biolabs or Pharmacia). The nucleotide sequences were determined on both DNA strands by the dideoxynucleotide chain termination method (27). Oligonucleotide primers were purchased from Gibco BRL. The primers ms7 (5'-TACCTGTTTGCTGTACTGCTGATGG) and ms3 (TTGCCGTTAATCCCAGACTCAC) were used.
Construction of the fimH mutant library.
The
656-bp KpnI-HincII fragment of the
fimH gene was mutagenized by nucleotide misincorporation
during suboptimal PCR conditions. Four reactions were performed with
three of the four nucleotides present at 50 mM and the other present at
5 mM. Each reaction mixture also contained 7 mM MgCl2 to
increase the stability of noncomplementary base pairs and 0.5 mM
MnCl2 to reduce the template specificity of the polymerase.
The error-prone PCR procedure was performed for 35 cycles with two
primers (ms7 and ms3) that flank the KpnI and
HincII sites of the fimH gene. The amplification products were combined, digested with KpnI and
HincII, purified after agarose gel electrophoresis, and
religated into similarly cut plasmid pMAS1 to construct a library of
altered fimH genes. This ligation mix was used to transform
S1918(pPKL115) cells. The transformation mixture was made up to 10 ml,
grown to approximately 10 times the initial library diversity, and
stored as aliquots at
80°C in 25% (vol/vol) glycerol.
Construction of defined fimH mutants. Gene changes encoding specific amino acid substitutions were introduced into the wild-type fimH sequence by exchange of restriction fragments from the mutant fimH genes. Unique restriction sites within the fimH gene permitted the exchange of these fragments using standard cloning procedures. Each construct was analyzed by restriction mapping and subsequent nucleotide sequencing. Plasmids containing these chimeric fimH genes were introduced into S1918(pPKL115) and tested in adhesion assays.
Agglutination of yeast cells. The capacity of bacteria to express a D-mannose-binding phenotype was assayed by their ability to agglutinate yeast (Saccharomyces cerevisiae) cells on glass slides. Aliquots of washed bacterial suspensions at an optical density at 550 nm (OD550) of 0.5 and 1% yeast cells were mixed, and the time until agglutination occurred was measured. Furthermore, clones which did not cause any agglutination under these conditions were also tested at OD550 = 20 and/or low temperature but still did not react.
Yeast cell aggregation assay.
Agglutination titers were
determined by mixing a suspension of E. coli cells (serially
diluted from OD530 = 0.4) with yeast cells (5 mg
ml
1 in phosphate-buffered saline [PBS]). Aggregation
was monitored visually, and the titer was recorded as the highest
dilution giving a positive aggregation result. For inhibition
experiments, bacteria (OD530 = 0.4) and yeast cells
were mixed with serial dilutions of
methyl-
-D-mannopyranoside solution and the results were
recorded as the highest dilution able to inhibit aggregation.
Adhesion assays.
Adhesion assays were performed essentially
as previously described (30). In short, wells were coated
with either yeast mannan, bovine RNase B (Sigma), or human plasma
fibronectin (obtained as described in reference 34)
at a concentration of 10 µg ml
1, washed three times
with PBS, and quenched with 0.2% bovine serum albumin (BSA) in PBS.
Bacterial suspensions containing identical cell numbers
(107 CFU/100 µl) were added to the wells and incubated at
37°C for 40 min. For determination of the mannose sensitivity of the
binding, this incubation was performed in the presence of 1%
methyl-
-D-mannopyranoside. The wells were washed with
PBS, and the number of bound bacteria was determined by a growth assay
as previously described (33).
-D-mannopyranoside) was determined as described above.
| |
RESULTS |
|---|
|
|
|---|
Construction of a fimH mutant library.
The FimH
adhesin confers the ability to bind to various receptor targets by
virtue of an NH2-terminal receptor-binding domain (16,
19). To identify specific amino acids involved in receptor target
recognition, we used the FimH expression vector pMAS1 (28). This vector contains the fimH gene from E. coli
K-12 strain PC31 (14) in pUC19 under transcriptional control
of the lac promoter. In addition, the plasmid contains
unique KpnI and HincII recognition sequences
within the fimH gene, which flank the region encoding the
proposed FimH receptor-binding domain (Fig. 1). Random mutagenesis was
performed on the 656-bp KpnI-HincII fragment of
fimH using a modified PCR and Taq DNA polymerase.
This polymerase possess an intrinsic error frequency under optimal
conditions of approximately 10
4 to 10
5
error per bp (37). The error-prone PCR amplification
products were digested with KpnI and HincII and
religated into similarly cut plasmid pMAS1 to reconstruct a library of
altered fimH genes (Fig. 1). To permit expression of the
corresponding FimH variants as functional constituents of type 1 fimbriae, the ligation mix was transformed into E. coli
strain S1918 (
fim) containing an auxiliary plasmid,
pPKL115, which encodes the entire fim gene cluster except
fimH. Using this approach, we have specifically targeted our
mutagenesis to the region encompassing amino acids 8 to 225 of the
mature FimH protein.
Selection of clones with altered FimH phenotypes from the mutant library. To determine the phenotypic mutant frequency of the FimH library, 300 transformant colonies were randomly picked and screened for their ability to agglutinate yeast cells, the traditional assay for monitoring type 1 fimbria-mediated binding. Of these, 44% were negative and 56% positive. Fifteen clones from the negative group and 50 clones from the positive group were randomly picked for further characterization of their binding profiles and tested for their ability to bind model receptor-specific targets. As relevant target substrates, we used yeast mannan (Mn), bovine RNase B (RB), fibronectin (Fn), and BSA. Mn represents the model substratum for terminal monomannose-specific binding, RB represents the model substratum for terminal oligomannose-specific binding, and Fn represents the model substratum for specific binding to oligosaccharides with no terminally exposed mannose residues; BSA served as a control substratum for monitoring of binding to protein substrates (30).
None of the clones that failed to agglutinate yeast cells in the initial screening were able to recognize any of the model substrates. Further studies revealed that all but one of these clones showed only marginal reaction with antiserum against type 1 fimbriae and purified FimH; i.e., they were similar to the fimH-null clone used as the negative control in these studies (data not shown). Indeed, sequence analysis of the corresponding fimH genes revealed that almost all of these clones had mutations in the fimH gene that would result in a truncated protein product. One of the nonagglutinating and nonbinding clones exhibited a relatively strong reaction with the anti-FimH serum and, possibly, expressed a nonfunctional FimH adhesin on the surface. In contrast to the agglutination-negative clones, all of the 50 agglutination-positive clones were able to bind at a detectable level to at least one of the model substrates. These results confirm the reliability of yeast agglutination as an efficient screening assay for the identification of clones that express functional FimH. The ability to bind model substrates was assessed quantitatively to differentiate between clones with unchanged phenotype, i.e. the wild-type-like adhesion, and those with a variant FimH phenotype. The wild-type-like clones were considered to be the ones that exhibited less than 50% deviation from the substrate-binding level of the control strain expressing the original FimH adhesin from E. coli K-12 strain PC31 (i.e., strain S1918 containing pPKL115 and pMAS1). According to this criterion, 37 clones (74%) had an unchanged binding phenotype while the remaining 13 (26%) clones demonstrated either a significantly lower or higher binding capability than the wild-type clone to at least one of the model substrates tested. Since this study focused on FimH adhesive phenotypes and not on mutations which altered the fimbriation level, the variant clones were tested for their ability to react with a polyclonal anti-type 1 fimbria antiserum and anti-FimH antiserum (data not shown). Two of the clones demonstrated a significantly lower ability to react with the anti-type 1 fimbrial serum compared to the wild-type control and were not studied further. The remaining 11 clones exhibited a wild-type-like interaction with the fimbrial and FimH antisera, and we therefore concluded that their variant adhesive phenotype resulted primarily from alteration of the FimH receptor-binding domain. All of these and two additional clones, randomly picked from the wild-type-like receptor-binding group, were subjected to the in-depth functional characterization and structural analysis outlined below.Detailed analysis of the functional variants of fimH.
The receptor-binding profiles of the variant, wild-type, and
wild-type-like clones are presented in Fig.
2A. Clones are listed based on the
ability to bind Mn, because the monomannose-specific binding was
previously shown to be the most variable property among naturally
occurring FimH isotypes (30). Interestingly, all variant
clones were able to bind the oligomannose-specific substrate, RB.
Although the binding range differed 10-fold, from 2.0 × 106 to 20.0 × 106 CFU/well, the average
difference from the wild-type level (8.0 × 106
CFU/well) was only 55.0% ± 11.4%. The same strains exhibited more
than a 150-fold range of Mn binding (from 0.05 × 106
to 8.7 × 106 CFU/well), with the average difference
from the wild-type level (1.7 × 106 CFU/well) being
161.4% ± 28.8% (r < 0.015). With regard to the other model substrates tested, only two clones, MS206 and MS243, were
identified which, in contrast to the wild type, had acquired the
ability to bind to Fn at detectable levels (Fig. 2A). No clones demonstrated an ability to bind the protein test substrate BSA (data
not shown). The results suggest that the parental monomannose-binding phenotype, assayed by binding to Mn, was the most sensitive to randomly
induced mutations, whereas the binding to the oligomannose target, RB,
seemed to be a property of the FimH adhesin that is relatively
resistant to structural alteration.
|
Agglutination and inhibition.
The classical assay for
monitoring type 1 fimbria-mediated adhesion to eucaryotic cells is
agglutination of erythrocytes or yeast cells. Yeast cell agglutination
is the most highly conserved binding property among natural E. coli isolates and was used in this study to evaluate the variation
in receptor binding exhibited by the fimH mutant clones
examined in this study. The ability to bind yeast was expressed as the
highest dilution of bacterial suspension that could confer
agglutination. Bacterial adhesion to eucaryotic cells under natural
conditions is a function of the ability of the adhesin to interact with
the cognate receptor on the cell surface but also depends on the
sensitivity of the adhesin to soluble inhibitory compounds that could
bathe the cellular target. Accordingly, we also determined the
sensitivity of the various clones to yeast cell agglutination in the
presence of a soluble inhibitor,
methyl-
-D-mannopyranoside.
|
Characterization of the amino acid substitutions introduced by
random mutagenesis.
The nucleotide sequences of the
fimH genes of the 11 variant and 2 wild-type-like clones
were determined; the corresponding amino acid sequences are presented
in Fig. 4. Overall, the PCR mutagenesis
of the 656-bp region of fimH resulted in one to four (an
average of two) nonsynonomus mutations per clone. The changes were
randomly distributed along the target sector, and the observed amino
acid changes were of diverse nature. It should be noted that the
nucleotide substitution rate gave an average of 3.5 substitutions per
clone; however, we have reported only the nucleotide changes which
alter the amino acid sequence of the protein. Taken together, these
data suggest that the PCR mutagenesis technique we used was an adequate
method for the introduction of a limited number of random structural
alterations in the FimH primary sequence.
|
Amino acid changes that confer shifts in receptor specificity. The majority of FimH variants identified in this study with altered phenotypes were found to contain multiple amino acid changes. To specifically define the functional impact of some of these individual substitutions, we took advantage of unique restriction sites to exchange segments with the wild-type fimH gene.
The group III clones are particularly interesting since their phenotype resembles those of naturally occurring FimH variants found in uropathogenic E. coli. Therefore, detailed analyses of these clones could provide information on the mechanism of natural selection of the FimH adhesin. Compared to the parental FimH, the mutant FimH expressed by the group III clone MS206 is characterized by a threefold increase in the ability to bind Mn (the monomannose-specific substrate) and in the acquired ability to bind human plasma Fn (the non-mannose-specific substrate). Two mutations were defined in the FimH-MS206 protein, G73E and L107F. When these changes were introduced separately into the parental FimH background, the G73E substitution was identified as the functionally critical one (Fig. 5). Interestingly, a G73E mutation has been identified as the functional change in a naturally occurring FimH variant that has a similar adhesive profile to MS206 (clone KB53, Fig. 2B) (34).
|
| |
DISCUSSION |
|---|
|
|
|---|
Most of the type 1-fimbriated E. coli strains of human fecal origin primarily recognize oligomannose-like receptors. In contrast, FimH variants that enable E. coli to bind strongly to monomannose-like receptors provide an adaptive advantage for the bacterial colonization of the urinary tract. Indeed, the monomannose-specific phenotype is dominant among uropathogenic E. coli isolates while the oligomannose phenotype is most common among fecal E. coli (31). A number of studies have attempted to define the integral parts of the FimH adhesin that contribute to receptor recognition. In-frame linker insertion mutagenesis of fimH in positions corresponding to amino acids 56 and 136 in the mature protein completely abolished the ability of FimH to bind to D-mannose receptors (29). Minor structural variations occurring naturally in the FimH adhesin that can lead to physiologically important changes in the pattern of receptor recognition have also been found primarily within the N-terminal half of the FimH protein (25, 34). Two studies involving fusions of sectors of FimH with either MalE or FocH showed that a segment encompassing amino acid residues 3 to 158 constituted a core region for receptor recognition, with additional information residing in the region from residues 159 to 201 (16, 35).
On this background, we created a mutant library by introduction of
mutations in the first two-thirds of the fimH gene from the
E. coli K-12 strain PC31 (whose sequence is identical to
that of the reference strain MG1655). Random mutagenesis was performed on the region covering bp 85 to 740 (codons 8 to 225) of the 900-bp fimH gene by PCR mutagenesis, the same sector previously
identified to encode the receptor recognition part of the adhesin. To
construct a library of altered fimH genes, the PCR
amplification products were exchanged with the wild-type gene copy in
plasmid pMAS1 and introduced into E. coli strain S1918
(
fim) containing an auxiliary plasmid, pPKL115, which
carries the entire fim gene cluster except fimH.
This permitted expression of the corresponding FimH variants as
functional constituents of type 1 fimbriae and therefore allowed specific phenotypic analysis of the mutants. Using this approach, we
were able to analyze a wide spectrum of FimH variants without alteration of the other fimbrial structural components, namely, FimA,
FimF, and FimG.
The PCR mutagenesis resulted in 44% of the mutants being nonfunctional, primarily due to the introduction of premature stop codons in the fimH gene. The bacterial clones containing truncated FimH proteins were unable to agglutinate yeast cells or bind to any of the model receptor substrates. These results concur with those of previous studies indicating that without the C-terminal region, which is critical for the interaction of FimH with the molecular chaperone FimC, the FimH protein is highly unstable and is not incorporated into the fimbrial organelle (9). These mutants were also characterized by a severe decrease in the number of fimbriae visualized at the cell surface, an observation consistent with the notion that FimH is involved in the initiation of fimbrial organelle synthesis.
The majority (56%) of the clones were capable of causing agglutination of yeast cells to various degrees. Fifty bacterial clones selected randomly from this group were all able to bind at least one of the model receptor substrates. Eleven of these clones (22%) exhibited a FimH-specific receptor-binding phenotype that differed significantly from that of the parental K-12 FimH. Detailed analyses of the functionally altered mutants revealed that the capacity of the FimH adhesin to recognize monomannose-like receptor substrates is highly prone to changes induced by the random mutagenesis while the oligomannose recognition phenotype is a much more stable functional property. This phenomenon corresponds to the pattern observed in naturally selected FimH variants, which are characterized by up to 15-fold variation in their ability to bind monomannose but by only minor deviations in their oligomannose-binding capacity (30).
Four (36%) of the functionally modified mutants (group III) closely resembled the natural pathogenicity-adaptive phenotype of FimH. In comparison to the original wild-type K-12 FimH, these clones were able to bind monomannose at a dramatically higher level, while their oligomannose-binding capability remained unchanged. In addition, two of these mutants exhibited binding to human plasma Fn, a phenotype highly specific to uropathogenic but not fecal E. coli isolates (32). Therefore, the naturally occurring pathogenicity-adaptive phenotype of the FimH adhesin could be induced at a relatively high rate under nonselective conditions. The G73E substitution, which was found to be responsible for the strong monomannose and Fn binding of the mutant clone MS206, has also previously been identified in the uropathogenic strain KB53 (33). However, the KB53 variant of fimH differs from the K-12 variant in four other positions, V27A, N70S, S78N, and H201D. Therefore, the G73E mutation imparts the same functional effect on two structurally different FimH alleles, suggesting that the same types of pathogenicity-adaptive mutations might provide the selective functional changes in various clonal variants of FimH across the E. coli species. The random mutagenesis has also provided strong evidence that the pathogenicity-adaptive phenotype of the FimH adhesin can be induced via a cumulative effect of two functionally neutral substitutions. Indeed, the L68F and S114R replacements do not affect the K-12 FimH phenotype as separate changes, but their simultaneous presence in the mutant clone MS243 dramatically increases the monomannose-binding capability. This would suggest that certain allelic variants of FimH that bear one of the neutral replacements would be more primed than other FimH alleles to evolve into the pathogenicity-adaptive variant.
The FimH mutant clone MS229 from group I and the two group IV clones demonstrate the most profound functional alterations of FimH since they affect its highly conserved oligomannose-binding property. Such types of functional alterations have not been previously observed among commensal or pathogenic isolates of E. coli. It is possible that the altered oligomannose-binding phenotype of the FimH protein is physiologically detrimental to E. coli in its natural environment. Indeed, the most distinctive clones from group I (MS229) and group IV (MS239) demonstrate a significantly decreased ability to bind to model target cells (yeast) and to overcome interference with adhesion by soluble inhibitors. It is possible, however, that such mutants do occur and are selectively advantageous under some yet unidentified natural conditions. The group I mutant clone MS229 contains the amino acid replacement P49Q that is responsible for abolishing the oligomannose-binding capability of the FimH adhesin, while the group IV clone MS239 demonstrates an increased oligomannose-binding capability due to the A25P substitution in its FimH. Interestingly, the P49Q substitution occurs in the YPETITD54 amino acid stretch that is homologous to the YPNTD16 region of the mannose-specific jack bean lectin, concanavalin A (ConA). Based on studies that have resolved the three-dimensional structure of the ConA lectin cocrystallized with trimannoside compounds, the YPNTD16 region of ConA is built by the residues that form a pocket capable of accommodating a complex oligomannose receptor structure (20). This would suggest that the P49 residue of FimH is part of its oligomannose-combining site. Further evidence that the P49 residue could be within the FimH receptor-binding site was provided by the X-ray structure of the FimH adhesin (in complex with the molecular chaperone, FimC) that was reported during the preparation of this paper (4). According to the X-ray study, the P49 residue is located within a pocket of the FimH protein that binds to a molecule of cyclohexylbutanoyl-N-hydroxyethyl-D-glucamide (C-HEGA). C-HEGA is not a known inhibitor of FimH-mediated mannose binding but was used as the cocrystallizing compound to obtain FimH-FimC crystals of the necessary quality. The defined carbohydrate-binding pocket was shown to accommodate only the glucamide moiety of C-HEGA, a relatively small molecule. Therefore, it is difficult to speculate how FimH interacts with larger receptor compounds like trimannose or with other known oligosaccharide inhibitors that exhibit 10- to 30-fold-higher binding affinity to FimH than does monomannose (6).
According to the reported structure of the FimH-FimC complex, the FimH
protein is folded into two domains, an NH2-terminal lectin
domain (residues 1 to 156) and a COOH-terminal pilin domain (residues
160 to 279). An important pattern emerges from the analysis of the
distribution of functional amino acid substitutions that have been
identified in this and previous studies (Fig.
6). The decreased binding capability of
FimH (i.e., group I clones) is caused by mutations that occur either
within or near the carbohydrate-interacting residues that form the
FimH-binding pocket at the tip of the jelly-roll-shaped lectin domain.
Conversely, the changes resulting in an increased monomannose-binding
capability of FimH (i.e., group III and IV clones) do not interact
directly with the mannose receptor site. Instead, these mutations occur
in the "bottom" part of the lectin domain. Such a mirror-image
distribution of the monomannose-binding enhancing substitutions is
highly nonrandom (P < 0.0001) and could not be
recognized without knowledge of the FimH crystal structure. Therefore,
the enhanced monomannose binding of the mutants is most probably
conformational, possibly due to alteration of the conformational
stability of the protein loops that carry the receptor-interacting residues. This type of phenomenon has also been observed in serine proteases, where substitution of such rigidity-providing residues has
been shown to result not in the abolition but in the broadening of
substrate specificity (24). This specificity-broadening
functional pattern is characteristic of the monomannose- and
fibronectin-binding FimH variants.
|
It is very likely that a thorough understanding of the structural and functional basis of the natural adaptability of the E. coli FimH adhesin will require cocrystallization of different FimH variants with various types of receptor molecules and, possibly, with other associated proteins within the fimbrial organelle structure. In this context, the FimH variants identified in this study constitute a well-defined group of variants based on the K-12 FimH allele. Studies on the adaptability of the E. coli FimH protein may serve as a model paradigm for the analysis of other bacterial adhesins or, basically, of any microbial traits that can be functionally modified by naturally occurring mutations to result in enhanced virulence.
| |
ACKNOWLEDGMENTS |
|---|
We thank Birthe Jul Jørgensen and Thomas B. Knudsen for expert technical assistance.
This work was supported by grants from the Danish Medical Research Council (9802358), the Danish Natural Sciences Research Council (9601682), the National Institutes of Health (P01 DK53369), and the Plasmid Foundation.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Microbiology, Bldg. 301, Technical University of Denmark, DK-2800 Lyngby, Denmark. Phone: 45-45-25-25-06. Fax: 45-45-93-28-09. E-mail: impk{at}pop.dtu.dk.
Editor: A. D. O'Brien
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Bloch, C. A., B. A. D. Stocker, and P. E. Orndorff. 1992. A key role for type 1 pili in enterobacterial communicability. Mol. Microbiol. 6:697-701[CrossRef][Medline]. |
| 2. | Boyer, H. W., and D. Roulland-Dussoix. 1969. A complementary analysis of the restriction and modification of DNA in Escherichia coli. J. Mol. Biol. 41:459-472[CrossRef][Medline]. |
| 3. |
Brown, S.
1992.
Engineering iron oxide-adhesion mutants of the Escherichia coli phage lambda receptor.
Proc. Natl. Acad. Sci. USA
89:8651-8655 |
| 4. |
Choudhury, D.,
A. Thompson,
V. Stojanoff,
S. Langermann,
J. Pinker,
S. J. Hultgren, and S. D. Knight.
1999.
X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli.
Science
285:1061-1066 |
| 5. |
Connell, H.,
W. Agace,
P. Klemm,
M. Schembri,
S. Mårild, and C. Svanborg.
1996.
Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract.
Proc. Natl. Acad. Sci. USA
93:9827-9832 |
| 6. |
Firon, N.,
I. Ofek, and N. Sharon.
1984.
Carbohydrate-binding sites of the mannose-specific fimbrial lectins of enterobacteria.
Infect. Immun.
43:1088-1090 |
| 7. |
Hanson, M. S.,
J. Hempel, and C. C. Brinton, Jr.
1988.
Purification of the Escherichia coli type 1 minor pilin proteins and partial characterization of the adhesin protein.
J. Bacteriol.
170:3350-3358 |
| 8. |
Jones, C. H.,
J. S. Pinkner,
A. V. Nicholes,
L. N. Slonin,
S. N. Abraham, and S. J. Hultgren.
1993.
FimC is a periplasmic PapD-like chaperone that directs assembly of type 1 pili in bacteria.
Proc. Natl. Acad. Sci. USA
90:8397-8401 |
| 9. |
Jones, C. H.,
J. S. Pinkner,
R. Roth,
J. Heuser,
A. V. Nicholes,
S. N. Abraham, and S. J. Hultgren.
1995.
FimH adhesin of type 1 pili is assembled into a fibrillar tip structure in the Enterobacteriaceae.
Proc. Natl. Acad. Sci. USA
92:2081-2085 |
| 10. | Klemm, P. 1992. FimC, a chaperone-like periplasmic protein of Escherichia coli involved in biogenesis of type 1 fimbriae. Res. Microbiol. 143:831-838[Medline]. |
| 11. | Klemm, P. (ed.). 1994. Fimbriae: adhesion, genetics, biogenesis and vaccines. CRC Press, Inc., Boca Raton, Fla. |
| 12. | Klemm, P., and G. Christiansen. 1987. Three fim genes required for the regulation of length and mediation of adhesion of Escherichia coli type 1 fimbriae. Mol. Gen. Genet. 208:439-445[CrossRef][Medline]. |
| 13. | Klemm, P., and G. Christiansen. 1990. The fimD gene required for cell surface localization of Escherichia coli type 1 fimbriae. Mol. Gen. Genet. 220:334-338[Medline]. |
| 14. | Klemm, P., B. J. Jørgensen, I. van Die, H. de Ree, and H. Bergmans. 1985. The fim genes responsible for synthesis of type 1 fimbriae in Escherichia coli. Mol. Gen. Genet. 199:410-414[CrossRef][Medline]. |
| 15. | Klemm, P., and K. A. Krogfelt. 1994. Type 1 fimbriae of Escherichia coli, p. 9-26. In P. Klemm (ed.), Fimbriae, adhesion, genetics, biogenesis and vaccines. CRC Press, Inc., Boca Raton, Fla. |
| 16. |
Knudsen, T. B., and P. Klemm.
1998.
Probing the receptor recognition site of the FimH adhesin by fimbriae-displayed FimH-FocH hybrids.
Microbiology
144:1919-1929 |
| 17. |
Krogfelt, K. A.,
H. Bergmans, and P. Klemm.
1990.
Direct evidence that the FimH protein is the mannose specific adhesin of Escherichia coli type 1 fimbriae.
Infect. Immun.
58:1995-1998 |
| 18. | Krogfelt, K. A., and P. Klemm. 1988. Investigation of minor components of Escherichia coli type 1 fimbriae: protein chemical and immunological aspects. Microb. Pathog. 4:231-238[CrossRef][Medline]. |
| 19. |
Langermann, S.,
S. Palaszynsky,
M. Barnhart,
G. Auguste,
J. S. Pinkner,
J. Burlein,
P. Barren,
S. Koenig,
S. Leath,
C. H. Jones, and S. J. Hultgren.
1997.
Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination.
Science
276:607-611 |
| 20. | Loris, R., T. Hamelryck, J. Bouckaert, and L. Wyns. 1998. Legume lectin structure. Biochim. Biophys. Acta 1383:9-36[CrossRef][Medline]. |
| 21. |
Lowe, M. A.,
S. C. Holt, and B. I. Eisenstein.
1987.
Immunoelectron microscopic analysis of elongation of type 1 fimbriae in Escherichia coli.
J. Bacteriol.
169:157-163 |
| 22. |
Mulvey, M. A.,
Y. S. Lopez-Boado,
C. L. Wilson,
R. Roth,
W. C. Parks,
J. Heuser, and S. J. Hultgren.
1998.
Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli.
Science
282:1494-1497 |
| 23. |
Pallesen, L.,
L. K. Poulsen,
G. Christiansen, and P. Klemm.
1995.
Chimeric FimH adhesin of type 1 fimbriae: a bacterial display system for heterologous sequences.
Microbiology
141:2839-2848 |
| 24. |
Perona, J. J., and C. S. Craik.
1997.
Evolutionary divergence of substrate specificity within the chymotrypsin-like serine protease fold.
J. Biol. Chem.
272:29987-29990 |
| 25. | Pouttu, R., T. Puustinen, R. Virkola, J. Hacker, P. Klemm, and T. K. Korhonen. 1999. Amino acid residue Ala-62 in the FimH fimbrial adhesin is critical for the adhesiveness meningitis-associated Escherichia coli to collagens. Mol. Microbiol. 31:1747-1757[CrossRef][Medline]. |
| 26. | Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 27. |
Sanger, F.,
S. Nicklen, and A. R. Coulson.
1977.
DNA sequencing with chain-terminating inhibitors.
Proc. Natl. Acad. Sci. USA
74:5463-5467 |
| 28. |
Schembri, M. A., and P. Klemm.
1998.
Heterobinary adhesins based on the Escherichia coli FimH fimbrial protein.
Appl. Environ. Microbiol.
64:1628-1633 |
| 29. | Schembri, M. A., L. Pallesen, H. Connell, D. L. Hasty, and P. Klemm. 1996. Linker insertion analysis of the FimH adhesin of type 1 fimbriae in an Escherichia coli fimH-null background. FEMS Microbiol. Lett. 137:257-263[CrossRef][Medline]. |
| 30. |
Sokurenko, E. V.,
V. Chesnokova,
R. J. Doyle, and D. L. Hasty.
1997.
Diversity of Escherichia coli type 1 fimbrial lectin.
J. Biol. Chem.
272:17880-17886 |
| 31. |
Sokurenko, E. V.,
V. Chesnokova,
D. E. Dykhuizen,
I. Ofek,
X.-R. Wu,
K. A. Krogfelt,
C. Struve,
M. A. Schembri, and D. L. Hasty.
1998.
Pathogenic adaptation of Escherichia coli by natural variation of the FimH adhesin.
Proc. Natl. Acad. Sci. USA
95:8922-8926 |
| 32. |
Sokurenko, E. V.,
H. S. Courtney,
S. N. Abraham,
P. Klemm, and D. L. Hasty.
1992.
Functional heterogeneity of type 1 fimbriae of Escherichia coli.
Infect. Immun.
60:4709-4719 |
| 33. |
Sokurenko, E. V.,
H. S. Courtney,
J. Maslow,
A. Sitonen, and D. L. Hasty.
1995.
Quantitative differences in adhesiveness of type 1 fimbriated Escherichia coli due to structural differences in fimH genes.
J. Bacteriol.
177:3680-3686 |
| 34. |
Sokurenko, E. V.,
H. S. Courtney,
D. E. Ohman,
P. Klemm, and D. L. Hasty.
1994.
FimH family of type 1 fimbrial adhesins: functional heterogeneity due to minor sequence variations among fimH genes.
J. Bacteriol.
176:748-755 |
| 35. | Thankavel, K., B. Madison, T. Ikeda, R. Malavia, A. H. Shah, P. M. Arumugam, and S. N. Abraham. 1997. Localization of a domain in the FimH adhesin of Escherichia coli type 1 fimbriae capable of receptor recognition and use of a domain-specific antibody to confer protection against experimental urinary tract infection. J. Clin. Investig. 100:1123-1136[Medline]. |
| 36. | Yamamoto, T., K. Fujita, and T. Yokota. 1990. Adherence characteristics to human intestinal mucosa of Escherichia coli isolated from patients with diarrhea or urinary tract infections. J. Infect. Dis. 162:896-908[Medline]. |
| 37. |
Zhou, Y.,
X. Zang, and R. Ebright.
1991.
Random mutagenesis of gene-sized DNA molecules by use of PCR with Taq DNA polymerase.
Nucleic Acid Res.
19:6052 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»